Cargando…

Sequential Treatment of Arsenic Trioxide Followed by All Trans Retinoic Acid with Anthracyclines has Excellent Long-Term Cure in Acute Promyelocytic Leukemia

Acute promyelocytic leukemia (APL) remains the most curable myeloid leukemia made feasible through effective use of two differentiating agents, all trans retinoic acid (ATRA) and arsenic trioxide (ATO) with or without chemotherapy (CT). However, early morbidity and mortality remains a problem. With...

Descripción completa

Detalles Bibliográficos
Autores principales:	Devadas, Santhosh Kumar, Jain, Hasmukh, Bagal, Bausaheb, Sengar, Manju, Dangi, Uma, Khattry, Navin, Amre, Pratibha, Patkar, Nikhil, Subramaniam, P. G., Nair, Reena, Menon, Hari
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer India 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7900266/ https://www.ncbi.nlm.nih.gov/pubmed/33692610 http://dx.doi.org/10.1007/s12288-020-01311-x

Ejemplares similares

Retinoic acid and arsenic trioxide in the treatment of acute promyelocytic leukemia: current perspectives
por: McCulloch, Derek, et al.
Publicado: (2017)

Role of cytogenetic abnormalities detected by fluorescence in situ hybridization as a prognostic marker: Pathogenesis & clinical course in patients with B-chronic lymphocytic leukaemia
por: Shetty, Dhanlaxmi, et al.
Publicado: (2021)

Molecular Heterogeneity in Acute Promyelocytic Leukemia - a Single Center Experience from India
por: Rabade, Nikhil, et al.
Publicado: (2018)

Retinoic acid and arsenic trioxide sensitize acute promyelocytic leukemia cells to ER stress
por: Masciarelli, S, et al.
Publicado: (2018)

All-trans-retinoic-acid and arsenic trioxide induced remission in promyelocytic blast crisis
por: Colvin, Teresa A., et al.
Publicado: (2018)

Retinoic acid and arsenic trioxide in the treatment of acute promyelocytic leukemia: current perspectives [Corrigendum]
Publicado: (2017)

P454: ACUTE MYELOID LEUKEMIA (AML) WITH IDH1 AND IDH2 MUTATIONS CAN BE EFFECTIVELY RISK STRATIFIED BASED ON THE PRESENCE ADVERSE RISK GENOMIC FEATURES.
por: Bhide, Aniket, et al.
Publicado: (2023)

Real world data with concurrent retinoic acid and arsenic trioxide for the treatment of acute promyelocytic leukemia
por: Kulkarni, Uday P., et al.
Publicado: (2022)

Flow cytometric evaluation of CD38 expression levels in the newly diagnosed T-cell acute lymphoblastic leukemia and the effect of chemotherapy on its expression in measurable residual disease, refractory disease and relapsed disease: an implication for anti-CD38 immunotherapy
por: Tembhare, Prashant Ramesh, et al.
Publicado: (2020)

Comparison of the efficacy and safety of Rituximab (Mabthera™) and its biosimilar (Reditux™) in diffuse large B-cell lymphoma patients treated with chemo-immunotherapy: A retrospective analysis
por: Roy, Partha Sarathi, et al.
Publicado: (2013)

Thrombocytosis in a patient with acute promyelocytic leukemia during treatment with all‐trans retinoic acid and arsenic trioxide
por: Habibi, Maryam, et al.
Publicado: (2021)

P360: MEASURABLE/MINIMAL RESIDUAL DISEASE (MRD) STATUS IS THE MOST RELEVANT INDICATOR OF CLINICAL OUTCOME IN MIXED PHENOTYPIC ACUTE LEUKEMIAS (MPAL)
por: Tembhare, Prashant, et al.
Publicado: (2023)

Fucoidan enhances the therapeutic potential of arsenic trioxide and all-trans retinoic acid in acute promyelocytic leukemia, in vitro and in vivo
por: Atashrazm, Farzaneh, et al.
Publicado: (2016)

Acute Promyelocytic Leukemia and Brugada Syndrome: A Report on the Safety of Arsenic Trioxide/All-Trans-Retinoic Acid Therapy
por: Rosati, Giorgio, et al.
Publicado: (2023)

Hematopoietic Stem Cell Transplantation in Acute Promyelocytic Leukemia in the Era of All-Trans Retinoic Acid (ATRA) and Arsenic Trioxide (ATO)
por: Colita, Andrei, et al.
Publicado: (2023)

Clinical impact of measurable residual disease monitoring by ultradeep next generation sequencing in NPM1 mutated acute myeloid leukemia
por: Patkar, Nikhil, et al.
Publicado: (2018)

Correction: Clinical impact of measurable residual disease monitoring by ultradeep next generation sequencing in NPM1 mutated acute myeloid leukemia
por: Patkar, Nikhil, et al.
Publicado: (2019)

Clinical impact of panel-based error-corrected next generation sequencing versus flow cytometry to detect measurable residual disease (MRD) in acute myeloid leukemia (AML)
por: Patkar, Nikhil, et al.
Publicado: (2021)

Real-World Outcomes With Generic Pomalidomide in Relapsed Refractory Multiple Myeloma—Experience From a Tertiary Care Cancer Center
por: Bondili, Suresh Kumar, et al.
Publicado: (2021)

All-Trans Retinoic Acid plus Arsenic Trioxide versus All-Trans Retinoic Acid plus Chemotherapy for Newly Diagnosed Acute Promyelocytic Leukemia: A Meta-Analysis
por: Ma, Yafang, et al.
Publicado: (2016)

Budgetary Impact of Treating Acute Promyelocytic Leukemia Patients with First-Line Arsenic Trioxide and Retinoic Acid from an Italian Payer Perspective
por: Kruse, Morgan, et al.
Publicado: (2015)

Two cases of differentiation syndrome with ocular manifestations in patients with acute promyelocytic leukaemia treated with all-trans retinoic acid and arsenic trioxide
por: Newman, A.R., et al.
Publicado: (2018)

All-trans retinoic acid and arsenic trioxide fail to derepress the monocytic differentiation driver Irf8 in acute promyelocytic leukemia cells
por: Liu, XiangZhen, et al.
Publicado: (2017)

A novel machine-learning-derived genetic score correlates with measurable residual disease and is highly predictive of outcome in acute myeloid leukemia with mutated NPM1
por: Patkar, Nikhil, et al.
Publicado: (2019)

A Review of Arsenic Trioxide and Acute Promyelocytic Leukemia
por: Alimoghaddam, Kamran
Publicado: (2014)

On arsenic trioxide in the clinical treatment of acute promyelocytic leukemia
por: Zhang, Peng
Publicado: (2017)

P003: A retrospective study to evaluate the reliability of staging and risk stratification of adolescent and adult patients with Hodgkin’s lymphoma registered in the lymphoma clinic at Tata Memorial Centre.
por: Jain, Hasmukh, et al.
Publicado: (2022)

Utility of Immunophenotypic Measurable Residual Disease in Adult Acute Myeloid Leukemia—Real-World Context
por: Patkar, Nikhil, et al.
Publicado: (2019)

Machine learning derived genomics driven prognostication for acute myeloid leukemia with RUNX1-RUNX1T1
por: Shaikh, Anam Fatima, et al.
Publicado: (2020)

Role of cytarabine in paediatric acute promyelocytic leukemia treated with the combination of all-trans retinoic acid and arsenic trioxide: a randomized controlled trial
por: Zhang, Li, et al.
Publicado: (2018)

Efficacy and Tolerability of First Line Arsenic Trioxide in Combination With All-Trans Retinoic Acid in Patients With Acute Promyelocytic Leukemia: Real Life Experience
por: Autore, Francesco, et al.
Publicado: (2021)

Infection Prevalence in Adolescents and Adults With Acute Myeloid Leukemia Treated in an Indian Tertiary Care Center
por: Jain, Hasmukh, et al.
Publicado: (2020)

Treatment of Acute Promyelocytic Leukemia with Single-Agent Arsenic Trioxide
por: Mathews, Vikram, et al.
Publicado: (2011)

Treatment outcome of all-trans retinoic acid/anthracycline combination chemotherapy and the prognostic impact of FLT3/ITD mutation in acute promyelocytic leukemia patients
por: Hong, Seung-Dok, et al.
Publicado: (2011)

Mutations of Epigenetic Modifier Genes as a Poor Prognostic Factor in Acute Promyelocytic Leukemia Under Treatment With All-Trans Retinoic Acid and Arsenic Trioxide
por: Shen, Yang, et al.
Publicado: (2015)

Walking a Tightrope: Dosage Modifications and Treatment Outcomes of All-Trans-Retinoic Acid, Arsenic Trioxide, and Daunorubicin for High-Risk Acute Promyelocytic Leukemia
por: Danthala, Madhav, et al.
Publicado: (2020)

An effective and chemotherapy-free strategy of all-trans retinoic acid and arsenic trioxide for acute promyelocytic leukemia in all risk groups (APL15 trial)
por: Wang, Huai-Yu, et al.
Publicado: (2022)

Retinoic Acid and Arsenic for Treating Acute Promyelocytic Leukemia
por: Zhou, Guang-Biao, et al.
Publicado: (2005)

Splenic marginal zone lymphoma relapsing as miliary lung mottling: an unusual presentation
por: Mandal, Tanmoy, et al.
Publicado: (2018)

Metabolic adaptation drives arsenic trioxide resistance in acute promyelocytic leukemia
por: Balasundaram, Nithya, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_nbfjp9o802bv6hfssi8nhag3vb